Generex Biotechnology Announces the Launch of a New Corporate Website

Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce
that the company has relaunched its corporate website to provide details
on a revamped organizational structure, a talented and experienced
management team, and a forward-looking vision for Generex as an
integrated life science holdings company. Generex is building a new kind
of healthcare company that extends beyond traditional models providing
support to physicians in an MSO network, and ongoing relationships with
patients to improve the patient experience and access to optimal care.
You can visit the site at www.generex.com.

Generex has reorganized its portfolio of immuno-oncology assets, medical
devices, and diagnostics as a family of NuGenerex subsidiary companies,
and expanded the business focus through acquisitions of strategic
businesses that complement existing assets and provide immediate sources
of revenue and working capital. Recent acquisitions include a management
services organization (MSO) with a network of over 400 physicians and
expansion opportunities from 5 to 27 states, a network of pharmacies
across the U.S., a clinical laboratory with specialty diagnostic
services, and two regenerative medicine companies, Regentys and Olaregen
that have been announced this week.

Our newly formed, wholly-owned subsidiary, NuGenerex Distribution
Solutions (NDS), integrates our MSO network with a pharmacy network,
clinical diagnostic lab, durable medical equipment company (DME-IQ) and
dedicated call center.

“We have worked diligently over the last two years on this considerable
reorganization, and we are proud to share the results of our efforts and
our vision for the future of Generex Biotechnology as a healthcare
holding company that adds significant value for our shareholders and
investors,” said Joe Moscato, CEO of Generex. “We have organized our
businesses as independently operating subsidiaries under the umbrella of
the NuGenerex Family of Companies, highlighting the intra-company
synergies that allow for cross-company business and integrated sales.
Further, we are acquiring companies like Regentys and Olaregen that fit
with our strategic model to provide end-to-end solutions for patients
and doctors. As you will see when you visit the site, we have
transformed Generex into a new kind of healthcare company, with
proprietary products and service lines that drive revenue to support the
clinical development of innovative therapies and value for our
investors.”

About Generex Biotechnology Corp.

Generex Biotechnology is an integrated healthcare holding company with
end-to-end solutions for patient centric care from rapid diagnosis
through delivery of personalized therapies. Generex is building a new
kind of healthcare company that extends beyond traditional models
providing support to physicians in an MSO network, and ongoing
relationships with patients to improve the patient experience and access
to optimal care.

In addition to advancing a legacy portfolio of immune-oncology assets,
medical devices, and diagnostics, the Company is focused on an
acquisition strategy of strategic businesses that complement existing
assets and provide immediate sources of revenue and working capital.
Recent acquisitions include a management services organization, a
network of pharmacies, clinical laboratory, and medical device companies
with new and approved products.

Our newly formed, wholly-owned subsidiary, NuGenerex Distribution
Solutions (NDS), integrates our MSO network with a pharmacy network,
clinical diagnostic lab, durable medical equipment company (DME-IQ) and
dedicated call center.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex
representatives in respect of the same subject matter may contain
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements can be
identified by introductory words such as "expects," "plan," "believes,"
"will," "achieve," "anticipate," "would," "should," "subject to" or
words of similar meaning, and by the fact that they do not relate
strictly to historical or current facts. Forward-looking statements
frequently are used in discussing potential product applications,
potential collaborations, product development activities, clinical
studies, regulatory submissions and approvals, and similar operating
matters. Many factors may cause actual results to differ from
forward-looking statements, including inaccurate assumptions and a broad
variety of risks and uncertainties, some of which are known and others
of which are not. Known risks and uncertainties include those identified
from time to time in the reports filed by Generex with the Securities
and Exchange Commission, which should be considered together with any
forward-looking statement. No forward-looking statement is a guarantee
of future results or events, and one should avoid placing undue reliance
on such statements. Generex undertakes no obligation to update publicly
any forward-looking statements, whether as a result of new information,
future events or otherwise. Generex claims the protection of the
safe harbor for forward-looking statements that is contained in the
Private Securities Litigation Reform Act.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190108005349/en/